Omid Hamid MD

Dr. Omid Hamid is the Director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute, he works to ensure that patients receive access to the most up-to-date therapeutics. Most recently, in his role with the Phase 1 Developmental Therapeutics Program, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. These therapies involve Immuno-Oncologic therapies such as PD-1 inhibitors (Keytruda, Nivolumab, Atezolizumab) and other checkpoint inhibitors, therapies against tumor angiogenesis, and targeted agents that block internal processes in tumor cell’s function. Dr. Hamid’s research focus involves the manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity and the discovery of novel therapies. His research began in melanoma and has now extended into paradigm-shifting trials for all cancers. 

Dr. Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics. Through his role as the Chief of Immunotherapy and Translational Research patients at The Angeles Clinic have benefited from first-in-class, paradigm-shifting drugs. Dr. Hamid was an investigator in the initial trials with Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab, and Vemurafenib, agents that led to significant survival benefits in the lives of our patients. Through his leadership, the next phase of agents has become available to our patients. He has been a key investigator in combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies and continues to be at the forefront of drug development. His current work focuses on Next-Generation Checkpoint Inhibitors including anti-OX40, 41BB, and GITR antibodies with a focus on bringing T-cell adoptive therapies and bispecific antibodies to our program. 

Dr. Hamid has presented research done at The Angeles Clinic at major national and international meetings including the American Society of Clinical Oncology (ASCO), Society for Melanoma Research, and many other key national and international meetings. He has published manuscripts, abstracts, and reviews on immunotherapy, targeted therapy, and melanoma care in prestigious journals such as the Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), and Clinical Cancer Research.